Now’s the Time to Buy Undervalued Canadian Stocks


Oh Canada!

Dollarama (DOL)

Valeant Pharmaceutical (VRX)


I’ve traveled to Canada on several occasions and been fortunate enough to visit most of the provinces that border the United States. Until my son started school in Vancouver in 2007 (he’s now graduated and teaching in Japan), I knew little about the economy of Canada and the companies that flourish there.

But during those five years, I became intrigued by Canada’s cities, farms, mountains, rivers and lakes, as well as its culture, prosperity and way of life. Canadians seem laid back and appreciative of their surroundings.

I also learned that the old saying: “When the U.S. sneezes, Canada catches pneumonia” isn’t true. Certainly, the Canadian economy follows in the footsteps of the U.S. economy, but the volatility of the Canadian economy seems considerably less than in the U.S. The financial crisis of four years ago was avoided in Canada because Canadian banks were not allowed to lower their lending standards and were required to retain their conservative investments.

The Canadian economy performed much better than the U.S. economy and many foreign economies during the Great Recession. In fact, the Canadian economy had the smallest downturn during the last four years of any G-7 country, which include the United States, Canada, France, Germany, Italy, the United Kingdom and Japan.

As of the end of the second quarter, Canada's housing market is ranked seventh best in the world. The banking sector is also healthy, and prices for precious metals are beginning to increase after falling during the past 12 months. Rising precious metals prices will help the country’s huge mining industry.

The Toronto Stock Exchange is the major stock exchange in Canada—although the New York Stock Exchange is 18 times the size of the Toronto Exchange in terms of dollar volume.

The Toronto Stock Exchange (TSX) Index, which is somewhat over-weighted in natural resource and bank stocks, outperformed the Standard & Poor’s 500 (S&P 500) Index from 2006 through 2010 but then faltered in 2011 and 2012. Indeed, the Toronto Stock Exchange Index has underperformed the S&P 500 by 22.9% from the end of 2010 to today due to the falling metals prices. But I predict the pendulum will swing in favor of the TSX soon.

For all these reasons, I believe now is an excellent time to buy undervalued Canadian stocks.

I have recommended Canadian stocks in my Cabot Benjamin Graham Value Letter on nine occasions during the past 30 months. My Canadian recommendations are up 53% compared to a minuscule 1% gain for the TSX. Am I a genius who can easily pick winning stocks? … No, but I apply my Benjamin Graham value screens to each stock to identify rapidly growing earnings and strong balance sheets … and I think now is a particularly good time to buy undervalued Canadian stocks with excellent appreciation potential.

Want an Annual Return of 15% plus generous dividend yields?

The objective of my ultra-low-risk investing system promises to help you find the
strongest dividend stocks, no matter the market environment. My system also finds
faster growing companies before they initiate dividends.

You'll be able to take advantage of margins of safety and Maximum Buy and
Minimum Sell Prices designed to boost your portfolio's gains while also protecting
you from the whipsaw action of dips and corrections.

Just look at these gains which my subscribers earned in 2013:

  • Advance Auto Parts UP 81%
  • Celgene UP 105%
  • eBay UP 89%
  • LKQ Corp. UP 123%
  • Reinsurance Group UP 70%
  • TJX Companies UP 133%

My system is simple: buy high-quality stocks when they are undervalued, and
sell when the stocks become overvalued. Buy low and sell high – it doesn't get any simpler!

Click here for more Roy Ward picks!

I believe many outstanding buying opportunities now exist among undervalued Canadian stocks. To uncover the stocks with the greatest opportunity, I screened my Benjamin Graham Database to find companies with rapidly growing earnings and strong balance sheets.

In my opinion, these two companies offer excellent appreciation potential during the next one to two years:

Dollarama (TSX: DOL 62.48) trades on the Toronto Stock Exchange only. With headquarters in Montreal, it’s the leading dollar store operator in Canada with 735 stores in all 10 provinces. In comparison, the second largest dollar store operator in Canada has only 125 stores. More than 500 of Dollarama's stores are located in Ontario and Quebec.

The company offers a broad range of general merchandise for $3 or less. Offerings include party supplies, seasonal merchandise, household products and cleaning supplies, paper and plastic products, health and beauty care products, food, novelty items and impulse products. All of Dollarama’s stores are corporate-owned and provide a consistent shopping experience.

The Canadian dollar store industry remains under-penetrated relative to the U.S. dollar store industry. On a per capita basis, there are 14,000 people per dollar store in the U.S. compared to 30,000 people per dollar store in Canada. Dollarama is opening stores rapidly to fill that dollar store void in Canada.

Dollarama’s sales increased 14% and EPS jumped 36% for the six months ended 7/31/12. Same-store sales advanced an impressive 7.7%, and sales and earnings growth has been consistent during the last several quarters. The company opened 31 new stores during the past six months.

I forecast Dollarama’s sales will increase 14% to $1.95 billion and earnings per share will rise 25% to 3.25 during the next 12 months ending 6/30/13. The price-to-earnings ratio of 19.2 is high, but if the company continues to perform well, I believe the stock can move substantially higher. The dividend was raised earlier this year and now yields 0.7%. The stock is a sleeper that very few investors are following.

The balance sheet is strong with little debt and ample cash. I recommend buying DOL at the current price.

Valeant Pharmaceuticals (NYSE: VRX 55.27), based in Mississauga, near Toronto, is an international specialty pharmaceutical company that discovers, develops, manufactures and markets a broad range of pharmaceutical products.

Valeant has developed drugs in almost all areas of medicine with a slightly higher emphasis on neurology and dermatology products. The company’s drugs include prescription as well as generic brands, and it markets about 900 pharmaceutical products globally.

The 2010 merger with Biovail tripled Valeant’s sales. The marriage has produced better than expected results featuring a vast array of products and marketing capabilities throughout the world.

Valeant’s enhanced management team is aggressively acquiring small companies with potential to immediately add earnings (commonly called accretive). The company is also expanding rapidly into emerging markets. In 2012, Valeant has already purchased a sports food supplement business in Brazil, a U.S. marketer of therapeutic products for macular degeneration and four other companies. All six companies will be accretive to Valeant’s earnings.

Valeant has acquired 50 companies during the past four years. Management recently announced its biggest deal since the merger with Biovail: Medicis Pharmaceutical for $2.4 billion. The purchase is due to be completed during the first or second quarter of 2013 and will be immediately accretive to Valeant’s earnings. In addition, Valeant expects to achieve at least $0.75 per share in annual cost synergies within the first six months after closing.

Sales will likely increase 20% and earnings per share will climb 25% during the next 12 months. My forecast does not include results from the Medicis purchase. The price-to-earnings ratio of 11.9 is a bargain, even though the company pays no dividend. The balance sheet is solid, although debt is a tad high.

Valeant is another sleeper that is lightly followed even though the company is now quite large. VRX should reach my 95.29 target price within one to two years.

I will continue to follow Dollarama, Valeant and other Canadian companies in my Cabot Benjamin Graham Value Letter. My October issue, coming soon, will focus on six new undervalued Canadian stocks. I hope you won’t miss it!


J.Royden Ward
Editor of Benjamin Graham Value Letter

Editor’s Note: You can find additional stocks selling at bargain prices in the Cabot Benjamin Graham Value Letter. In every issue, you’ll find my legendary Maximum Buy and Minimum Sell Prices for over 250 stocks.

"This is ideal for a conservative investor even if you are experienced and sophisticated."--J. C. Denton, Ph.D., Belton, Texas

Click here to get started today!

more Value Investing

Stock Picks

Prudential Financial

This stock currently stands out because it easily fits all of Benjamin Graham's criteria.


This stock is still behaving well, supported by the buying power of investors just discovering the stock.


A good value with excellent prospects for recovery because homebuilding is strong.

Cabot Wealth Advisory

For Investors with a Taste for Adventure

By Paul Goodwin on February 04, 2016

For investors with a little taste for adventure, emerging markets are more fun than an unlimited ticket to a go-cart track (and offer much bigger potential rewards). Yes, when markets turn sour, emerging market stocks can take some skin off. But that only happens if you’re sitting like a bump on a log and watching your holdings tank.Read More >

How to Benefit from Daily Trading Order Flow

By Jacob Mintz on February 02, 2016

As the market was unwinding, the question I often heard from subscribers of Cabot Options Trader and Cabot Options Trader Pro, was “what stocks were on your watch list to buy?” My answer was always the same: look at the Daily Order Flow Reading email that I send every day for the best ideas on what to short and what to buy.Read More >

Apple (AAPL) and Zika

By Timothy Lutts on February 01, 2016

Read More >